Please login to the form below

Not currently logged in
Email:
Password:

AZ discontinues asthma medicine

AstraZeneca is to discontinue production of an inhaled version of its asthma medication Pulmicort due to 'manufacturing issues'

AstraZeneca (AZ) is to discontinue production of the pressurised metered dose inhaler (pMDI) version of its asthma medication Pulmicort (budesonide), in both its 100µg and 200µg doses, due to 'manufacturing issues'.

The company said the problem is due to 'product-specific processes and components', the combination of which was used solely in the manufacturing of Pulmicort pMDI.

The decision to discontinue the product was not related to the active ingredient of the medicine, budesonide - a corticosteroid also used in AZ's nasal inhalant, Rhinocort, for conditions such as hayfever, and the controlled-release capsule Entocort for Crohn's disease.

Other unaffected products include AZ's Pulmicort Turbuhaler, Pulmicort Respules and Pulmicort Flexhaler.

David Smith, executive vice president, Global Operations and IS, AstraZeneca, said the company had "exhausted all potential solutions" in its efforts to solve the technical problems and to continue supplying the product.

"[I]t is in the patient's best interest to find an alternative medication as soon as possible," continued Smith, with AZ stating that it is working with regulatory authorities and healthcare professionals to help patients on Pulmicort pMDI to switch treatments.

Patients currently on the medication will be able to finish any current supplies they have remaining.

7th March 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....